Drugs / VRC01.23LS
VRC01.23LS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05959707 | Aug 2024 → Jan 2025 | HIV infectious disease | HIV Vaccine Trials Network | Suspended | No outcome recorded |
| Phase 1 | NCT05627258 | Jan 2023 → Jul 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC01.23LS | “VRC01.23LS, a broadly neutralizing monoclonal antibody targeting the HIV-1 envelope CD4 binding site.” NCT05627258 ↗ |
| Known as | VRC-HIVMAB-0115-AB | “VRC-HIVMAB-0115-AB (VRC01.23LS)” NCT05627258 ↗ |
| Known as | VRCHIVMAB0115-00-AB | “VRCHIVMAB0115-00-AB (VRC01.23LS)” NCT05627258 ↗ |
| Modality | Monoclonal antibody | “broadly neutralizing monoclonal antibody” NCT05627258 ↗ |
| Route | Intravenous | “subcutaneous (SC) and intravenous (IV) administrations” NCT05627258 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) and intravenous (IV) administrations” NCT05627258 ↗ |